Intracranial hemorrhage during dabigatran treatment - Case series of eight patients -

Circulation Journal

Volumn 78, Issue 6, 2014, Pages 1335-1341

  Komori, Motohiro ^a   Yasaka, Masahiro ^a   Kokuba, Kazuhito ^a   Matsuoka, Hideki ^d   Fujimoto, Shigeru ^e   Yoshida, Megumu ^f   Kameda, Katsuharu ^g   Shono, Tadahisa ^g   Nagata, Shinji ^b   Ago, Tetsuro ^c   Kitazono, Takanari ^c   Okada, Yasushi ^a  

^a Clinical Research Institute   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

^e STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^f Shin Kokura Hospital   (Japan)

^g HARASANSHIN HOSPITAL   (Japan)

Author keywords

Blood pressure; Dabigatran; Intracranial hemorrhage; Novel oral anticoagulant

Indexed keywords

DABIGATRAN; PROTHROMBIN COMPLEX; RIVAROXABAN; WARFARIN; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

AGED; ARTICLE; BRAIN CONTUSION; BRAIN HEMORRHAGE; BURR HOLE EVACUATION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PUTAMINAL HEMORRHAGE; RETROSPECTIVE STUDY; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; UNRUPTURED INTRACRANIAL ANEURYSM; VERY ELDERLY; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; BLOOD; CASE REPORT; CHEMICALLY INDUCED; INTRACRANIAL HEMORRHAGES; PATHOPHYSIOLOGY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE;

EID: 84901308605     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1534     Document Type: Article

References (23)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151 and Erratum in: N Engl J Med 2010; 363: 1877.
2. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
3. Lip GY, Lane DA. Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation: Focus on the elderly. Circ J 2013; 77: 1380-1388.
4. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. Stroke 2008; 39: 1740-1745.
5. Kuwashiro T, Yasaka M, Itabashi R, Nakagaki H, Miyashita F, Naritomi H, et al. Enlargement of acute intracerebral hematomas in patients on long-term warfarin treatment. Cerebrovasc Dis 2010; 29: 446-453.
6. Suzuki S, Otsuka T, Sagara K, Matsuno S, Funada R, Uejima T, et al. Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. Circ J 2012; 76: 755-757.
7. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100.
8. Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003; 89: 278-283.
9. del Zoppo GJ, Eliasziw M. New options in anticoagulation for atrial fibrillation. N Engl J Med 2011; 365: 952-953.
10. Sakata T, Kario K, Matsuo T, Katayama Y, Matsuyama T, Kato H, et al. Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 1995; 15: 241-246.
11. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF study. Circ J 2012; 76: 2104-2111.
12. Yasaka M. J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan. Circ J 2012; 76: 2086-2087.
13. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012; 76: 2337-2342.
14. Won SY, Schlunk F, Dinkel J, Karatas H, Leung W, Hayakawa K, et al. Imaging of contrast medium extravasation in anticoagulationassociated intracerebral hemorrhage with dual-energy computed to mography. Stroke 2013; 44: 2883-2890.
15. Lauer A, Cianchetti FA, Van Cott EM, Schlunk F, Schulz E, Pfeilschifter W, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation 2011; 124: 1654-1662.
16. Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-315.
17. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al. Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44: 1891-1896.
18. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke 2012; 43: 1511-1517.
19. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
20. Simonsen CZ, Steiner T, Tietze A, Damgaard D. Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion. J Stroke Cerebrovasc Dis 2014; 23: e133-e134, doi: 10. 1016/j. jstrokecerebrovasdis. 2013. 08. 011.
21. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: Functional and structural characterization. Blood 2013; 121: 3554-3562.
22. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl 1): S141-S145.
23. Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol 2013; 26: 191-202.